ArticleCancer immunology, immunotherapy : CII2026

A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer.

Weihong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.